PDCD1 and neoplasm: Efforts to restore latent anti-tumor immunity have focused on monoclonal antibody (mAb)-based interventions targeting CTL antigen 4 (CTLA-4)5,6 and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells.